Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study.

导出 LinkOut

翻译打印收藏纠错

作者： Konrad,Rejdak ^[1] ; Adriana,Zasybska ^[1] ; Aleksandra,Pietruczuk ^[1] ; Dariusz,Baranowski ^[1] ; Sebastian,Szklener ^[1] ; Magda,Kaczmarek ^[1] ; Zbigniew,Stelmasiak ^[1]

作者单位： Department of Neurology, Medical University of Lublin, 20-594 Lublin, Poland. ^[1]

关键词 long-term efficacy relapsing multiple sclerosis safety subcutaneous cladribine

DOI 10.3390/jcm10215207

PMID 34768726

发布时间 2021-11-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of clinical medicine

2021年10卷21期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study.

Journal of clinical medicine

相似文献

Journal of clinical medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study.

Journal of clinical medicine

相似文献

Journal of clinical medicine

相关期刊

检索历史清除